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BACKGROUND Portico (St. Jude Medical) and CoreValve (Med-
tronic) are both nitinol based self-expanding transcatheter heart valves
with unique features enabling device retrievability for Portico and su-
pra annular valve position for CoreValve systems. In this study, we
sought to investigate the effect of the different self-expanding valve
design on hemodynamic and clinical performance when implanted for
degenerated aortic valve bioprosthesis (valve in valve, ViV).
METHODS Patients undergoing Portico implantation for degenerated
aortic bioprosthesis were compared to those undergoing CoreValve
implantation after matching for differences in age, gender, STS score,
arterial access, bioprosthesis valve design and label size in a 1:2
manner. Procedural and clinical outcomes were deﬁned by Valve
Academic Research Consortium II (VARC-II).
RESULTS A total of 135 patients that underwent ViV using a self-
expanding device were included in the analysis (age 798yrs, 61.5%
female). The group included 45 Portico implantations that were
matched with 90 CoreValve ViV patients having similar patient and
surgical valve characteristics. Baseline demographic and procedural
characteristics, echocardiographic and clinical outcomes are detailed
in the table. There were no differences in any procedural character-
istics between the two groups, except for the external transcatheter
valve diameter selected being signiﬁcantly greater for the CoreValve
ViV and proportion of patients undergoing procedure under
general anesthesia and with TEE guidance, which was signiﬁcantly
higher for the Portico group. Clinical outcomes were similar except
for major vascular complications that were signiﬁcantly lower in
Portico implantations. Site reported echocardiographic parameters
showed a greater proportion of patients with more than mild aortic
insufﬁciency after the procedure and a smaller effective oriﬁce area
for the Portico compared to CoreValve group. Blinded core lab analysis
of post implantation imaging of all cases analyzed is being completed.CONCLUSIONS Despite important design differences between the
two self-expanding transcatheter valves, both devices were safe
and effective for management of degenerated aortic bioprosthesis.
The present study has identiﬁed dissimilarities in hemodynamic
performance and clinical outcomes that require conﬁrmation in
future studies.Portico
(n[45)CoreValve
(n[90) P valueBaseline characteristicsSTS score, mean  SD 7.5  3.7 8.1  5.2 0.11
THV external
diameter, mean 
SD24  1 26  2 <0.05Clinical outcomes at 30 daysDeath, n (%) 1 (2.2) 4 (4.7) 0.5Stroke, n (%) 1 (2) 2 (2) 1Major vascular
complication, n (%)1 (2) 8 (9) 0.03Coronary obstruction
(%)0 (0) 4 (4.6) 0.30Malposition, n (%) 0 (0) 5 (6.0) 0.16Second prosthesis, n
(%)0 (0) 5 (5.6) 0.17Permanent pacemaker,
n (%)1 (3) 5 (6) 0.67> Mild aortic
insufﬁciency n (%)8 (18) 4 (5) 0.02EOA cm2, mean  SD 1.3  0.4 1.5  0.4 0.03
Mean gradient mmHg ,
mean  SD
17.1 8 15.5 8 0.30AKI- Acute Kidney Injury, EOA-effective oriﬁce area, PPM-permanent pacemaker, LVEF-left ventricle ejection
fraction, STS-Society of Thoracic Surgery score, TEE-transesophageal echocardiography, THV- Transcatheter
Heart Valve.
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BACKGROUND Transcatheter aortic valve replacement (TAVR) has
been established as alternative treatment for inoperable or high-risk
patients with symptomatic severe aortic stenosis. We sought to
evaluate the clinical outcomes of TAVR in Asian Paciﬁc countries.
METHODS The Asian TAVR registry was conducted in 12 centres from
6 countries between February 2009 and February 2015. Baseline de-
mographics, procedural and echocardiographic data were prospec-
tively collected from each center and entered into dedicated
electronic case report form.
RESULTS Nine hundred and forty patients were included. Mean
age was 82.1  6.5 years and 52.9% were female. Edwards SAPIEN/XT
and CoreValve were used in 65.4% and 34.6% of patients, respec-
tively. Approaches were either transarterial (transfemoral, 85.8%;
subclavian, 0.4%; direct aortic, 1.6%) or transapical (12.0%).
